With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck ...

Under the terms of the deal, MSD (known as Merck & Co in the US and Canada) is paying $30 million upfront for Modifi with up ...

Beijing is emerging as a global hub for pharmaceutical innovation as eight international pharmaceutical companies plan to establish research and development centers in the city.

Merck’s Keytruda receives European approval for two new indications in gynaecologic cancers: Rahway, New Jersey Friday, October 25, 2024, 09:00 Hrs [IST] Merck, known as MSD out ...

The US CDC has recommended lowering the age for pneumococcal vaccination from 65 to 50 to give more adults the opportunity to ...

Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, has been ...

After the disastrous performance of 2022, the market has recovered better than expected and is on a growth trajectory.

The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.

Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in ...

All adults aged 50 and older should receive a vaccine against bacteria that can cause pneumonia and meningitis, federal ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...

The U.S. Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between ...